Propionylpromazine: Unveiling a Novel Inhibitory Agent AgainstMycobacterium tuberculosis

ABSTRACT The emergence of multidrug-resistant mycobacterium tuberculosis presents a significant hurdle, as it shows resistance to existing standard therapies, underscoring the critical need for novel antibacterial agents. This study presents propionylpromazine as a promising compound with potent activity against M. tuberculosis . Our research indicates that propionylproma zine effectively curtails the proliferation of M. tuberculosis H37Rv. Importantly, propionylpromazine has shown the capability to impede the growth of M. tuberculosis within macrophages without causing detrimental effects. These findings endorse the potential of propionylpromazine to be further developed as a clinical drug for the effective treatment of M. tuberculosis infections.